

## Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025

Rupa R. Patel, MD<sup>1</sup>; Karen W. Hoover, MD<sup>1</sup>; Allison Lale, MD<sup>1</sup>; Janet Cabrales, PharmD<sup>1</sup>; Katrina M. Byrd, MD<sup>1</sup>; Athena P. Kourtis, MD, PhD<sup>1</sup>

### Abstract

In 2023, approximately 39,000 persons received a diagnosis of HIV in the United States. Although HIV preexposure prophylaxis (PrEP) is highly effective in preventing HIV infection, acceptance of, adherence to, and persistence taking the available oral and injectable PrEP regimens have been suboptimal. CDC PrEP guidelines published in 2021 include two oral tenofovir-based regimens and cabotegravir, the only injectable PrEP regimen approved by the Food and Drug Administration (FDA) at that time. In June 2025, FDA approved injectable lenacapavir (LEN), administered every 6 months, as HIV PrEP based on results from two randomized controlled trials (PURPOSE 1 and PURPOSE 2). The CDC PrEP Guidelines Work Group assessed evidence for the efficacy and safety of LEN PrEP using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The two trials reported LEN efficacy at reducing HIV infection as 100% among females and 96% among a primarily male trial population, compared with the estimated background HIV incidence (or no use of PrEP) over a follow-up of 52 weeks. No significant safety concerns were identified in the trials. The most common adverse events were mild (grade 1) to moderate (grade 2) injection site reactions. Based on a high certainty of evidence for the efficacy and safety of LEN as assessed by the GRADE analysis, subcutaneous injection of LEN every 6 months is strongly recommended as a PrEP option in persons weighing  $\geq 77$  lbs ( $\geq 35$  kg) who would benefit from PrEP. LEN has the potential to improve PrEP adherence and thus enhance HIV prevention in the United States.

### Introduction

In 2023, approximately 39,000 persons received a diagnosis of HIV in the United States (1). HIV preexposure prophylaxis (PrEP) is highly effective at preventing HIV infection (2,3); however, implementation has been challenged by low acceptance of, adherence to, and persistence taking currently available PrEP options in the United States: 1) daily oral tenofovir-based regimens and 2) injectable cabotegravir administered every 2 months (4–8). Multiple national assessments have found that approximately one half of oral daily PrEP users discontinue it within 6–12 months of beginning prophylaxis (4–6). On June 18, 2025, the Food and Drug Administration (FDA) approved injectable lenacapavir (LEN) for PrEP, an HIV-1 capsid inhibitor administered every 6 months (9).

This report presents the CDC 2024–2025 PrEP Guidelines Work Group's assessment of evidence from two randomized controlled trials (10,11) of the efficacy and safety of injectable LEN, administered every 6 months subcutaneously, for HIV PrEP, and provides a clinical recommendation for its use. The recommendation in this policy note updates the 2021 CDC PrEP Clinical Practice Guideline (12) by including LEN as an option for PrEP.

### INSIDE

550 Notes from the Field: Differences in Suicide Rates, by Race and Ethnicity and Age Group — United States, 2018–2023

Continuing Education examination available at [https://www.cdc.gov/mmwr/mmwr\\_continuingEducation.html](https://www.cdc.gov/mmwr/mmwr_continuingEducation.html)



U.S. DEPARTMENT OF  
HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE  
CONTROL AND PREVENTION

## Methods

### Guideline Development Process

This recommendation was drafted according to CDC's guideline development standards (13). The work group developed the LEN PrEP recommendations as an update to the 2021 CDC PrEP Clinical Practice Guideline (12) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (14). The CDC 2024–2025 PrEP Guidelines Work Group comprised members from CDC's Division of HIV Prevention who convened and met regularly during May 2024–January 2025. Members were selected for their experience (including clinical practice or research), expertise in PrEP-related topics, or experience in CDC guideline development. The work group generated a research question, conducted a systematic literature review, and synthesized evidence to guide work group discussions (14–16).

The focused research question for evidence synthesis was, "Should injectable LEN be included as an option for persons who would benefit from HIV PrEP?" The population, intervention, comparison, and outcomes (PICO) framework was used, and the components were as follows: adults and adolescents weighing  $\geq 77$  lbs ( $\geq 35$  kg) (weight criterion per LEN FDA label indication) who would benefit from PrEP for HIV (the population); LEN PrEP (the intervention); no or daily oral tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) PrEP (the comparison groups); and PrEP efficacy (HIV incidence rate ratio) compared with no PrEP use or

daily oral TDF/FTC use, adverse events (excluding injection site reactions), injection site reactions, and grade 3–5 adverse events (severe, life-threatening, or fatal adverse events) (the outcomes). LEN compared with injectable cabotegravir PrEP was not evaluated in the absence of randomized evidence comparing the two. All outcomes were deemed critical by the CDC 2024–2025 PrEP Guidelines Work Group to develop the LEN PrEP recommendations. The work group also considered acceptability, feasibility, resource use, and harms and benefits while developing the recommendations. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.\*

### Systematic Literature Review

The work group conducted a systematic literature search using Medline, Embase, Cochrane, CINAHL, Scopus, and [Clinicaltrials.gov](https://www.clinicaltrials.gov) databases to identify published, randomized controlled trials for the population and intervention from database inception through February 21, 2025. Two reviewers independently screened 62 titles and abstracts, excluding 60 records because they were 1) in a non-English language, 2) conference abstracts, 3) trial protocol listings, 4) HIV treatment studies, 5) pharmacokinetic trials, or 6) animal and molecular studies. Two full-text reports were reviewed and included for evidence synthesis; the GRADE assessments

\*45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

The *MMWR* series of publications is published by the Office of Science, U.S. Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

**Suggested citation:** [Author names; first three, then et al., if more than six.] [Report title]. *MMWR Morb Mortal Wkly Rep* 2025;74:[inclusive page numbers].

### U.S. Centers for Disease Control and Prevention

Jim O'Neill, MA, *Acting Director*  
Althea Grant-Lenzy, PhD, *Acting Director, Office of Science*

### MMWR Editorial and Production Staff (Weekly)

Michael Berkwits, MD, MSCE, *Editor in Chief*

Rachel Gorwitz, MD, MPH, *Acting Executive Editor*  
Jacqueline Gindler, MD, *Editor*  
Paul Z. Siegel, MD, MPH, *Associate Editor*  
Mary Dott, MD, MPH, *Online Editor*  
Terisa F. Rutledge, *Managing Editor*  
Catherine B. Lansdowne, MS,  
*Acting Lead Technical Writer-Editor*  
Stacy Simon, MA, Morgan Thompson,  
Suzanne Webb, PhD, MA,  
*Technical Writer-Editors*

Terraye M. Starr,  
*Acting Lead Health Communication Specialist*  
Alexander J. Gottardy,  
Maureen A. Leahy, Armina Velarde,  
*Visual Information Specialists*  
Quang M. Doan, MBA,  
Phyllis H. King, Moua Yang,  
*Information Technology Specialists*

Kiana Cohen, MPH,  
Leslie Hamlin, Lowery Johnson,  
*Health Communication Specialists*  
Will Yang, MA,  
*Visual Information Specialist*

### MMWR Editorial Board

Matthew L. Boulton, MD, MPH  
Carolyn Brooks, ScD, MA  
Virginia A. Caine, MD  
Jonathan E. Fielding, MD, MPH, MBA

Timothy F. Jones, MD, *Chairman*  
David W. Fleming, MD  
William E. Halperin, MD, DrPH, MPH  
Jewel Mullen, MD, MPH, MPA  
Jeff Niederdeppe, PhD  
Patricia Quinlisk, MD, MPH

Patrick L. Remington, MD, MPH  
Carlos Roig, MS, MA  
William Schaffner, MD  
Morgan Bobb Swanson, MD, PhD

were presented to the work group in February 2025 (Table 1) (Table 2). Recommendations were made by work group consensus (at least two thirds of votes). Work group members, none of whom reported conflicts of interest, reviewed the draft guidelines. The work group then created an external peer review plan, and the reviewers' comments were incorporated into the final document.

## Rationale and Evidence

### Clinical Efficacy Trials for LEN as HIV PrEP

The evidence base comprised two phase-3 multisite, double-blinded, randomized controlled clinical efficacy trials, PURPOSE 1 and PURPOSE 2, which were conducted during June 2021–September 2024 (10,11). The PURPOSE 1 trial enrolled females aged 16–25 years in South Africa and Uganda.<sup>†</sup> This trial compared HIV incidence among those who received injectable LEN every 6 months (using an initial 2 days of oral loading doses) with the estimated background HIV incidence in the screened population (no PrEP use; primary endpoint) and HIV incidence among participants who received daily oral TDF/FTC (secondary endpoint) (10). The PURPOSE 1 trial also assessed the efficacy of daily oral tenofovir alafenamide-emtricitabine (TAF/FTC), a medication that has not been approved by FDA as PrEP for women, compared with no PrEP use and daily oral TDF/FTC use, and assessed safety outcomes for LEN compared with both tenofovir-based options (10).

The PURPOSE 2 trial primarily enrolled males (see Table 1 in the trial report [11]) aged 16–80 years in 92 trial sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the United States. After screening the eligible trial population for HIV infection to establish background incidence, participants who tested negative were randomized to receive injectable LEN every 6 months or daily oral TDF/FTC (11). The trial's primary efficacy analysis compared HIV infection incidence in the LEN group with background HIV incidence in the screened population. The secondary efficacy analysis compared HIV infection incidence in the LEN group with the TDF/FTC group.

In both trials, study inclusion was based on the presence of sexual risk factors for HIV infection, and the randomized design was used for the secondary endpoint (daily oral PrEP

**TABLE 1. Efficacy evidence for injectable lenacapavir for HIV preexposure prophylaxis compared with no preexposure prophylaxis and daily oral preexposure prophylaxis — Grading of Recommendations, Assessment, Development and Evaluation, United States, 2025**

Factors	HIV infection comparison groups	
	Lenacapavir vs. background HIV incidence (no PrEP)	Lenacapavir vs. TDF/FTC
<b>Certainty assessment</b>		
No. of studies	Two*	Two*
Study design	Background incidence study design <sup>†</sup>	Randomized trials
Risk of bias <sup>§</sup>	Serious	Not serious
Inconsistency	Not serious	Not serious
Indirectness	Not serious	Not serious
Imprecision	Not serious	Not serious
Other considerations	Very strong association <sup>¶</sup>	None
<b>No. of HIV infections/No. of participants (mITT analysis)</b>		
Injectable lenacapavir	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>
	0/2,134	0/2,134
	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>
Comparator	2/2,179	2/2,179
	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>
	92/8,094	16/1,068
Effect estimate	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>
	45/4,634	9/1,086
	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>
Incidence rate ratio (95% CI)	0 (0–0.04)	0 (0–0.10)
	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>
	0.04 (0.01–0.18)	0.11 (0.02–0.51)
Certainty	High	High
Importance	Critical	Critical

**Abbreviations:** mITT = modified intention to treat; PrEP = preexposure prophylaxis; TDF/FTC = tenofovir disoproxil fumarate-emtricitabine.

\* Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. *N Engl J Med* 2024;391:1179–92. <https://doi.org/10.1056/NEJMoa2407001>; Kelley CF, Acevedo-Quinones M, Agwu AL, et al; PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. *N Engl J Med* 2025;392:1261–76. <https://doi.org/10.1056/NEJMoa2411858>.

<sup>†</sup> The comparison was based on a background incidence study design; the study design was nonrandomized.

<sup>§</sup> The Risk of Bias 2 tool was used to assess the risk for bias in both trials for the comparator of TDF/FTC (randomized trials) and the ROBINS-I tool (Risk of Bias in Non-Randomized Studies of Interventions) for the comparator of background HIV incidence (nonrandomized trials).

<sup>¶</sup> Association (threshold of rate ratio <0.20) observed between the intervention and the outcome when compared with the comparator group.

use comparator), whereas the background incidence design was used for the primary endpoint (no PrEP use comparator) (Table 1) (10,11). In both trials, follow-up visits occurred at 4, 8, and 13 weeks, as well as every 13 weeks thereafter. Testing at follow-up visits included blood-based rapid antigen and antibody (antigen/antibody) tests and central laboratory antigen/antibody tests. HIV RNA testing was available for participants who acquired HIV infection during the trial (10,11).

<sup>†</sup> PURPOSE 1 trial inclusion criteria: 1) females; 2) aged 16–25 years; 3) sexually active with male partners; 4) not using PrEP; and 5) unknown HIV status or no HIV test within the 3 months preceding study enrollment. PURPOSE 2 trial inclusion criteria: 1) aged ≥16 years; 2) predominantly males; 3) have condomless receptive anal sex with male partners; 4) unknown HIV status; and 5) no HIV test or PrEP use within the 3 months preceding study enrollment.

**TABLE 2. Adverse events from injectable lenacapavir for HIV preexposure prophylaxis compared with daily oral preexposure prophylaxis — Grading of Recommendations, Assessment, Development and Evaluation, United States, 2025**

Factors	Adverse events		
	Any grade (excluding injection site reactions)	Grade 3, 4, or 5* (including injection site reactions)	Injection site reaction (any grade)
<b>Certainty assessment</b>			
No. of studies	Two <sup>†</sup>	Two <sup>†</sup>	Two <sup>†</sup>
Study design	Randomized trials	Randomized trials	Randomized trials
Risk of bias	Not serious	Not serious	Not serious
Inconsistency	Not serious	Not serious	Not serious
Indirectness	Not serious	Not serious	Not serious
Imprecision	Not serious	Not serious	Not serious
Other considerations	None	None	None
<b>No. of adverse events/No. of participants (%)</b>			
Injectable lenacapavir	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>
	1,631/2,138 (76.3)	92/2,138 (4.3)	1,470/2,138 (68.8)
	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>
Oral daily TDF/FTC	1,607/2,183 (73.6)	104/2,183 (4.8)	1,816/2,183 (83.2)
	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>	<b>PURPOSE 1</b>
	830/1,070 (77.6)	52/1,070 (4.9)	363/1,070 (33.9)
Certainty	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>	<b>PURPOSE 2</b>
	803/1,088 (73.8)	66/1,088 (6.1)	756/1,088 (69.5)
Importance	High	High	High
	Critical	Critical	Critical

**Abbreviation:** TDF/FTC = tenofovir disoproxil fumarate-emtricitabine.

\* Severe (grade 3), life-threatening (grade 4), or fatal (grade 5) adverse events.

<sup>†</sup> Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. *N Engl J Med* 2024;391:1179–92. <https://doi.org/10.1056/NEJMoa2407001>; Kelley CF, Acevedo-Quinones M, Agwu AL, et al; PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. *N Engl J Med* 2025;392:1261–76. <https://doi.org/10.1056/NEJMoa2411858>.

A preplanned interim analysis was conducted when 50% of the target population had been enrolled for  $\geq 52$  weeks. After the interim analysis, independent data monitoring committees terminated the blinded phase of both trials based on the prespecified efficacy criteria<sup>§</sup> (10,11).

### PURPOSE 1 Clinical Efficacy Trial

The PURPOSE 1 trial included a total of 8,094 females who were screened and included in calculating the background HIV incidence; 5,338 females were enrolled in the modified intention-to-treat (mITT) analysis in a 2:1:1 design (2,134: LEN plus an oral placebo; 2,136: TAF/FTC plus an injection placebo; and 1,068: TDF/FTC plus an injection placebo) (10). No new HIV infections occurred among females receiving injectable LEN over 52 weeks of follow-up. Within

this group, LEN was 100% efficacious compared with no use of PrEP (incidence rate ratio [IRR] = 0; 95% CI = 0–0.04) and with TDF/FTC (IRR = 0; 95% CI = 0–0.10) (10). In the postprimary analysis, two participants with incident HIV infection were identified in the LEN group. One of the incident infections occurred in a participant after discontinuation of LEN during a period in which drug concentrations decreased below the target levels necessary for protection against HIV. No HIV-1 capsid inhibitor mutations were detected (9). The second participant in the LEN group with an incident HIV infection had a low HIV viral load, and genotyping to detect LEN resistance-associated mutations was not possible (9).

### PURPOSE 2 Clinical Efficacy Trial

The PURPOSE 2 trial included a total of 4,634 participants (see Table 1 in the trial report for details on demographics [11]) who were screened and included in calculating the background HIV incidence; 3,265 participants were enrolled in the mITT analysis in a 2:1 design (2,179 LEN plus an oral placebo and 1,086 TDF/FTC plus an injection placebo) (11). In this study, LEN was 96% efficacious in preventing HIV infection compared with no PrEP use (IRR = 0.04; 95% CI = 0.01–0.18) and 89% efficacious compared with TDF/FTC (IRR = 0.11; 95% CI = 0.02–0.51) (11). Two HIV infections occurred in participants receiving LEN; in both cases, drug concentrations were within ranges expected to be protective, and the HIV-1 capsid mutation N74D was detected. One of the participants with an incident HIV infection had a viral load of 14,000 HIV copies/mL; HIV diagnostic assays were notable for negative rapid test results and positive laboratory-based antigen/antibody test results at diagnosis. The other participant had a viral load of 934,000 HIV copies/mL; both the rapid and the laboratory-based antigen/antibody test results were positive at diagnosis (11). In the postprimary analysis, one additional incident HIV infection was identified in the LEN group, and Q67H/K70R mutations in the capsid gene were detected (9).

### Safety and Adverse Events

Rates of any adverse events of any grade (excluding injection site reactions) and of grade 3 (severe), 4 (life-threatening), or 5 (fatal) adverse events were similar in all study groups in both trials (10,11). Deaths that occurred were determined to be unrelated to the study drug. Adverse events of grades 3–5 were more prevalent in the TDF/FTC group. Injection site reactions were the most commonly reported adverse event in all study groups in both trials. They occurred more often in the LEN group (PURPOSE 1 = 68.8%; PURPOSE 2 = 83.2%), were mainly grade 1 (mild) or grade 2 (moderate), and predominantly included pain,

<sup>§</sup> An interim efficacy analysis was conducted when 50% of participants had completed 52 weeks of the study or discontinued the study early. The efficacy endpoint was the rate of HIV infection per 100 person-years in the LEN group compared with the rate of HIV infection per 100 person-years in the oral tenofovir-based PrEP group. The PURPOSE 1 and PURPOSE 2 trials were stopped early because LEN was found to be superior to no use of PrEP and to the use of TDF/FTC. As a result, the interim efficacy analysis constituted the primary efficacy analysis.



subcutaneous nodules, and induration. Symptom intensity and frequency decreased with subsequent injections. LEN discontinuations related to injection site reactions were infrequent (PURPOSE 1 = 0.2%; PURPOSE 2 = 1.2%) (10,11). In the postprimary analysis, nodules persisted for a median of 350 days (IQR = 182–470 days) in the PURPOSE 1 trial and 297 days (IQR = 176–423 days) in the PURPOSE 2 trial (9). The median diameter of the largest nodule per participant was 1.2 inches (3.0 cm) (IQR = 0.8–1.6 inches [2–4 cm]) (11).

Among 510 pregnancies that occurred among 487 women in PURPOSE 1, pregnancy-associated adverse events and pregnancy outcomes were comparable in the 184 participants receiving LEN and those receiving tenofovir-based PrEP, both consistent with background rates; no adverse events were reported among breastfed infants exposed to LEN (10). No HIV infections occurred among pregnant women who received LEN; five infections occurred in the tenofovir-based PrEP groups (10).

The overall certainty of evidence for the five outcomes assessed was high based on GRADE. LEN is highly efficacious (Table 1) and safe (Table 2) as PrEP. The most commonly reported adverse event was an injection site reaction, which led to few discontinuations.

### Clinical Recommendation for Use of Lenacapavir for HIV Prevention

Lenacapavir, administered as subcutaneous injections every 6 months, is recommended as an HIV PrEP option in persons weighing  $\geq 77$  lbs ( $\geq 35$  kg) who would benefit from PrEP. This is a strong recommendation, based on high certainty of evidence.

### Clinical Guidance for Use of Lenacapavir for HIV Prevention

#### Identification of Persons Eligible to Receive LEN

Clinicians should consider PrEP in persons whose behaviors and epidemiologic context place them at risk for HIV acquisition (12). These populations include but are not limited to those with identified high HIV incidence in the United States (including persons with diagnosed sexually transmitted infections, men who have sex with men, persons whose sexual partners have HIV infection without viral suppression, persons who engage in transactional sex, persons who are incarcerated, and persons who share needles). PrEP should be offered in addition to other evidence-based HIV prevention strategies and within a comprehensive primary care strategy (12).

Clinicians should educate all eligible persons about current available PrEP options, discuss product choice, provide follow-up and medication adherence support, reassess ongoing risk,

and align PrEP care goals accordingly (12). LEN might offer a good option for persons who prefer not to take a daily oral pill. The National Clinician Consultation Center PrEPLine (855-448-7737) and the [National HIV PrEP Curriculum](#) can provide guidance for prescribing PrEP medications.

Assessing eligibility for LEN consists of 1) assessing HIV acquisition risk, 2) excluding those with acute HIV infection, and 3) identifying significant drug interactions or contraindications (Box) ([Supplementary Table](#)) (9,17,18). Based on the limited available safety and efficacy data, LEN PrEP may be used in pregnant women or continued in women who become pregnant while receiving injections, considering the woman's risk for HIV without PrEP, after provider-client shared decision-making.

#### Recommended Laboratory Testing

To rule out recent HIV infection, laboratory blood-based HIV antigen/antibody testing is recommended on the day of the initial LEN injection and with follow-up injections; however, LEN may also be administered if testing occurred within the preceding 7 days (Box). At initiation of LEN PrEP, a confirmatory HIV RNA test should be obtained in addition to the antigen/antibody test, if available; however, the results of the RNA assay should not delay injection (9). If HIV RNA testing is not available, a repeat laboratory-based antigen/antibody test should be scheduled in 4 weeks to exclude an undetected baseline infection (12). For those who receive positive HIV test results, confirmatory and other testing should be performed and treatment initiated; for treatment of HIV infections that were acquired after receiving LEN, integrase strand-transfer inhibitor-based therapy should be considered ([Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 2024](#)).

If clinicians administer follow-up LEN injections based on a negative rapid HIV antigen/antibody test result, a confirmatory laboratory-based antigen/antibody test should also be obtained. Oral HIV antibody tests should not be used because of their low sensitivity in detecting recent HIV infection (12). If initiating LEN as a switch from tenofovir-based or cabotegravir PrEP without any interruption, only a laboratory-based HIV antigen/antibody test is needed before the injection. Tenofovir is an antiviral that can be used to treat chronic hepatitis B infection. Therefore, clinicians switching persons from tenofovir-based PrEP to LEN PrEP should determine whether the client has HBV infection or is immune to HBV. For persons with HBV infection, an alternative HBV treatment regimen should be provided if tenofovir is discontinued. HBV vaccination should be administered if a person is not immune to HBV (19,20).

## BOX. Clinical considerations\* for injectable lenacapavir for HIV preexposure prophylaxis — United States, 2025

**Eligibility**

- **Weight  $\geq 77$  lbs ( $\geq 35$  kg) and at risk for HIV acquisition<sup>†</sup>**
- **No signs or symptoms of acute HIV infection.** If acute HIV infection is suspected, appropriate clinical care is recommended, including HIV RNA testing.
- **Negative blood-based HIV antigen/antibody test result within 7 days before first lenacapavir (LEN) dose**
- **Negative confirmatory HIV RNA test, if available.** However, results of RNA assay should not delay initial LEN injection. Obtain up-to-date individual contact information to relay any positive test results and next steps.
- **Negative blood-based HIV antigen/antibody test result (no confirmatory RNA test needed) when switching from oral tenofovir-based or cabotegravir preexposure prophylaxis (PrEP) without interruption<sup>§</sup>**
- **No known significant drug interactions or contraindications.** Significant drug interactions and supplemental LEN dosing are available from the Food and Drug Administration (FDA) in the [LEN prescribing information](#).

**Dosage**

Significant drug interactions and supplemental LEN dosing are available from FDA in the [LEN prescribing information](#).

- **Loading**
  - Day 1: 927 mg (3 mL) LEN by subcutaneous injection (two 1.5-mL injections at least 4 inches apart) and 600 mg orally (two 300-mg tablets)<sup>¶</sup>
  - Day 2: 600 mg LEN orally (two 300-mg tablets)
- **Maintenance:** Every 6 months (26 weeks)  $\pm 2$  weeks, from the date of the last injection, 927 mg (3 mL) LEN by subcutaneous injection (two 1.5-mL injections at least 4 inches apart)<sup>¶</sup>

**Drug-Drug Interactions**

Significant drug interactions and supplemental LEN dosing are available from FDA in the [LEN prescribing information](#).

- Coadministration of strong and moderate cytochrome P450 3A (CYP3A) inducers requires supplemental LEN dosing.
- LEN increases the concentration of certain medications for up to 9 months after the last injection, requiring dose adjustments and monitoring for side effects.

**Initiation: First Visit**

- Assess eligibility and provide loading dose after shared decision-making.
- Provide information on adverse reactions, including injection site reactions, and recommendations, should a reaction occur.

- Review the schedule for follow-up visits and scenarios if an injection is missed.
- Screen for sexually transmitted infections (STIs) (vaginal, oral, rectal, urine, or blood, as needed) and viral hepatitis, and consider doxycycline postexposure prophylaxis.<sup>\*\*</sup> Plan for follow-up STI screening based on risk, which might be more frequent than LEN visits.
- Provide support for behavioral risk reduction, follow-up, primary care, reproductive health, substance use, mental health, social needs, or other services, as needed.
- When switching clients from tenofovir-based PrEP, ensure they do not have hepatitis B virus (HBV) infection or are HBV immune. Initiate an alternate HBV treatment regimen for HBV-infected clients if tenofovir is discontinued. Provide HBV vaccination to clients who are not HBV immune.<sup>††</sup>

**Follow Up: Every 6 Months, or More Frequently as Needed**

More frequent interactions (e.g., texting and telephone calls) to follow up about adverse events, social support, and other care needs might be necessary, especially at the beginning of therapy; consider an initial follow-up at 1 month.

- Administer maintenance LEN injection.
- Assess for signs and symptoms of acute HIV infection. If acute HIV infection is suspected, appropriate clinical care is recommended, including HIV RNA testing.
- Negative HIV antigen/antibody test result.<sup>§</sup>
- Identify significant drug interactions or contraindications. Significant drug interactions and supplemental LEN dosing are available from FDA in the [LEN prescribing information](#).
- Assess for adverse reactions, including injection site reactions.
- Reassess HIV risk and PrEP needs and preferences.
- Screen for STIs (vaginal, oral, rectal, urine, or blood, as needed); consider doxycycline PEP.<sup>\*\*</sup>
- Provide support for behavioral risk reduction, follow-up primary care, reproductive health, substance use, mental health, social needs, or other services as needed.

**Discontinuation of LEN**

- Inform PrEP users that when LEN is discontinued, medication levels in the body decline over 18 months, starting 6 months after the last injection, and do not offer HIV protection after 6 months; the period of declining medication levels over time is called the tail.
- Assess ongoing HIV risk and prevention plans and offer other PrEP options.

See footnotes on the next page.

## BOX. (Continued) Clinical considerations\* for injectable lenacapavir for HIV preexposure prophylaxis — United States, 2025

**Planned Missed Injection****Oral bridging (weekly oral maintenance) if a maintenance injection is anticipated to be  $\geq 14$  days late**

- Prescribe a maintenance dose of 300-mg LEN orally every 7 days for <6 months (<26 weeks). The first oral dose should be taken 6 months after the last LEN injection. Resume the maintenance LEN injection within 7 days after the last oral LEN dose.
- If oral LEN is not feasible during the planned missed maintenance injections, prescribe another form of PrEP until maintenance LEN injections resume.
- If maintenance injections cannot resume after 6 months of oral LEN bridging, then prescribe another form of PrEP.

**Unplanned Missed Injection****Maintenance injection  $\geq 14$  days late and oral LEN bridging has not been taken in the interim**

- Evaluate the reason LEN was missed, determine whether restarting is appropriate, and reinstate as discussed previously (i.e., eligibility assessment, testing with HIV antigen/antibody and RNA tests, and prescribing, including loading dose).
- If LEN is not continued, see the Discontinuation section for counseling and offering other forms of PrEP.

**Time to Protection**

- Limited data suggest protective levels of LEN are achieved 2 hours after the dose on day 2, if both days of oral loading are taken ([Lenacapavir dosing in special situations: tuberculosis and beyond](#)).
- If both days of oral loading are missed, time to protection is estimated to be 21–28 days.

**Pregnancy, Lactation, and Breastfeeding**

- Limited human data on the use of LEN during pregnancy, lactation, and breastfeeding suggest no increases in drug-associated risks for adverse pregnancy, birth, and infant outcomes when compared with daily tenofovir-based PrEP or background rates.
- LEN PrEP may be used in pregnant women or continued in women who become pregnant while receiving injections, considering the woman's risk for HIV without PrEP, after provider-client shared decision-making.
- Women should be encouraged to notify their providers if they are planning to conceive, become pregnant, or breastfeed.
- Health care staff members are encouraged to submit information on pregnancies during PrEP use to the [Antiretroviral Pregnancy Registry online](#) or by telephone: 800-258-4263.

\* The following clinical considerations are based on the [2021 CDC PrEP Clinical Practice Guideline](#) and are supplemented with data from the [Food and Drug Administration \(FDA\) label](#) and other references. The recommendation updates the 2021 guideline by including lenacapavir (LEN) as an option for preexposure prophylaxis (PrEP).

† Clinicians should consider PrEP in persons whose behaviors and epidemiologic context place them at risk for HIV acquisition (CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. <https://stacks.cdc.gov/view/cdc/112360>). These populations include but are not limited to those with identified high HIV incidence in the United States (including persons with diagnosed sexually transmitted infections, men who have sex with men, persons whose sexual partners have HIV infection without viral suppression, persons who engage in transactional sex, persons who are incarcerated, and persons who share needles).

§ See Recommended Laboratory Testing in report text for HIV screening recommendations. Perform confirmatory and other testing and initiate treatment for persons who receive positive HIV test results. For treatment of HIV infections acquired after receiving LEN, consider integrase strand-transfer inhibitor–based therapy ([U.S. Department of Health and Human Services | Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 2024](#)).

¶ Injection sites include the abdomen (at least 2 inches away from the navel) and anterior thigh. Additional sites that are being studied include the upper arm (Sources: Lat AK, Kim A, Zhang H, et al. 1542. Impact of subcutaneous administration sites on the clinical pharmacokinetics of lenacapavir, a long-acting HIV capsid inhibitor: does body site matter? Open Forum Infect Dis Vol. 10 (Suppl. 2):2023. <https://doi.org/10.1093/ofid/ofad500.1377>; Clinicaltrials.gov. [Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate \(F/TDF\) in Prevention of HIV in Cisgender Women in the United States \(HPTN 102\) \(PURPOSE 3\)](#)).

\*\* Sources: *STI screening*: [CDC STI Treatment Guidelines](#). *Hepatitis B screening*: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1). <http://dx.doi.org/10.15585/mmwr.rr6701a1>. *Hepatitis C screening*: [Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C](#). *Doxycycline PEP guidance*: Bachmann LH, Barbee LA, Chan P, et al. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep 2024;73(No. RR-2). <https://dx.doi.org/10.15585/mmwr.rr7302a1>.

†† Sources: *HBV vaccination*: Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:477–83. <https://dx.doi.org/10.15585/mmwr.mm7113a1>. *HBV treatment*: [American Association for the Study of Liver Diseases | Chronic Hepatitis B Practice Guideline](#).

**Summary****What is already known about this topic?**

HIV preexposure prophylaxis (PrEP) reduces HIV incidence; however, adherence to available PrEP regimens is suboptimal. In June 2025, FDA approved injectable lenacapavir (LEN) administered every 6 months as HIV PrEP, based on results from two randomized controlled trials (RCTs) that reported LEN efficacy at reducing HIV infection as 100% among females and 96% among a primarily male trial population over a follow-up of 52 weeks.

**What is added by this report?**

Based on efficacy and safety demonstrated by the two RCTs, the CDC PrEP Guidelines Work Group strongly recommends lenacapavir injections as an HIV PrEP option in persons weighing  $\geq 77$  lbs ( $\geq 35$  kg) who would benefit from PrEP.

**What are the implications for public health practice?**

LEN has the potential to improve PrEP adherence and thus enhance HIV prevention.

## 2024–2025 Lenacapavir for HIV Preexposure Prophylaxis Guideline CDC Work Group and Writing Team

Katrina M. Byrd, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Janet Cabrales, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Gema Dumitru, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Melanie Gwynn, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Karen W. Hoover, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Priya Jakhmola, Office of Science, Office of the Director, CDC; Allison Lale, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Athena P. Kourtis, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Jesse O'Shea, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Rupa R. Patel, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.

**External Reviewers**

Susan P. Buchbinder, San Francisco Department of Public Health; Monica Gandhi, University of California, San Francisco; Raphael J. Landovitz, University of California, Los Angeles.

**Acknowledgments**

Melanie Gwynn, Jesse O'Shea, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC; Priya Jakhmola, Joanna Taliano, Office of Science, CDC.

Corresponding author: Rupa R. Patel, [ntw4@cdc.gov](mailto:ntw4@cdc.gov).

<sup>1</sup>Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for the disclosure of any potential conflicts of interest. No potential conflicts of interest were reported.

**References**

1. CDC. HIV diagnoses, deaths, and prevalence: 2025 update. Atlanta, GA: US Department of Health and Human Services, CDC; 2025. <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-and-prevalence-2025.html>
2. Sullivan PS, Juhasz M, DuBose SN, et al. Association of state-level PrEP coverage and new HIV diagnoses in the USA from 2012 to 2022: an ecological analysis of the population impact of PrEP. *Lancet HIV* 2025;12:e440–8. PMID:40441808 [https://doi.org/10.1016/S2352-3018\(25\)00036-0](https://doi.org/10.1016/S2352-3018(25)00036-0)
3. Smith DK, Sullivan PS, Cadwell B, et al. Evidence of an association of increases in pre-exposure prophylaxis coverage with decreases in human immunodeficiency virus diagnosis rates in the United States, 2012–2016. *Clin Infect Dis* 2020;71:3144–51. PMID:32097453 <https://doi.org/10.1093/cid/ciz1229>

**LEN Initiation and Injection Site Reactions**

LEN is initiated with two 300-mg oral tablets (total 600 mg) each on days 1 and 2 (loading doses), along with two 1.5-mL subcutaneous injections (total 927 mg in 3 mL) administered in immediate sequence at least 4 inches apart on day 1 (9). Injection sites include the abdomen and anterior thigh (9). LEN forms a drug depot that might result in a subcutaneous nodule. Nodules are the most frequently reported injection site reaction. Nodules can be several centimeters in size and can last for several months to more than a year (9,11). Other injection site reactions include pain and induration. Incorrect injection technique, such as inserting the needle at an angle of  $\leq 45^\circ$  (resulting in intradermal rather than subcutaneous injection), is thought to contribute to injection site reactions (11). The manufacturer recommends an injection angle of  $90^\circ$ . Application of ice packs and use of topical and oral analgesics before and after injection might alleviate some signs and symptoms related to injection site reactions.

**Conclusion and Future Research**

LEN is a highly effective and safe PrEP option administered every 6 months, which provides the potential to improve PrEP adherence and thus enhance HIV prevention in the United States. Additional research is needed to understand LEN's effectiveness in persons who inject drugs, its ability to inhibit early viral replication if a person receiving PrEP becomes infected, the potential for emergence of resistance, safety and efficacy over longer follow-up periods, acceptability, and optimal strategies for implementation in clinical and community settings (21,22).



4. McCormick CD, Sullivan PS, Qato DM, Crawford SY, Schumock GT, Lee TA. Adherence and persistence of HIV pre-exposure prophylaxis use in the United States. *Pharmacoepidemiol Drug Saf* 2024;33:e5729. PMID:37937883 <https://doi.org/10.1002/pds.5729>
5. Huang YA, Tao G, Smith DK, Hoover KW. Persistence with human immunodeficiency virus pre-exposure prophylaxis in the United States, 2012–2017. *Clin Infect Dis* 2021;72:379–85. PMID:33527117 <https://doi.org/10.1093/cid/ciaa037>
6. Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. *J Int AIDS Soc* 2019;22:e25252. PMID:30775846 <https://doi.org/10.1002/jia2.25252>
7. Landovitz RJ, Donnell D, Clement ME, et al.; HPTN 083 Study Team. Cabotegravir for HIV prevention in cisgender men and transgender women. *N Engl J Med* 2021;385:595–608. PMID:34379922 <https://doi.org/10.1056/NEJMoa2101016>
8. Delany-Moretlwe S, Hughes JP, Bock P, et al.; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. *Lancet* 2022;399:1779–89. PMID:35378077 [https://doi.org/10.1016/S0140-6736\(22\)00538-4](https://doi.org/10.1016/S0140-6736(22)00538-4)
9. Food and Drug Administration. YEZTUGO (lenacapavir) tablets, for oral use; YEZTUGO (lenacapavir) injection, for subcutaneous use. Prescribing information. Silver Spring, MD: Food and Drug Administration; 2025. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/220020s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf)
10. Bekker LG, Das M, Abdool Karim Q, et al.; PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. *N Engl J Med* 2024;391:1179–92. PMID:39046157 <https://doi.org/10.1056/NEJMoa2407001>
11. Kelley CF, Acevedo-Quinones M, Agwu AL, et al.; PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. *N Engl J Med* 2025;392:1261–76. PMID:39602624 <https://doi.org/10.1056/NEJMoa2411858>
12. CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. <https://stacks.cdc.gov/view/cdc/112360>
13. Carande-Kulis V, Elder RW, Koffman DM. Standards required for the development of CDC evidence-based guidelines. *MMWR Suppl* 2022;71(Suppl 1):1–6. PMID:35025853 <https://doi.org/10.15585/mmwr.su7101a1>
14. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6. PMID:18436948 <https://doi.org/10.1136/bmj.39489.470347.AD>
15. Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S. Determining the scope of the review and the questions it will address [Chapter 2]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. *Cochrane handbook for systematic reviews of interventions*. Version 6.5. Oxford, England: The Cochrane Collaboration; 2024. <https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-02>
16. Alonso-Coello P, Schünemann HJ, Moberg J, et al.; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. *BMJ* 2016;353:i2016. PMID:27353417 <https://doi.org/10.1136/bmj.i2016>
17. University of Liverpool. HIV drug interactions checker. Liverpool, United Kingdom; 2025. <https://hiv-druginteractions.org/checker>
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: US Department of Health and Human Services; 2024. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new>
19. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:477–83. PMID:35358162 <https://doi.org/10.15585/mmwr.mm7113a1>
20. Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and clinical management of chronic hepatitis B. *Hepatology* 2018;67:1546–59. PMID:29405329
21. Gilead Sciences. HPTN103: PURPOSE 4. Foster City, CA: Gilead Sciences; 2025. <https://www.purposestudies.com/purpose4>
22. Walensky RP, Baden LR. The real PURPOSE of PrEP—effectiveness, not efficacy. *N Engl J Med* 2024;391:1246–7. PMID:39046168 <https://doi.org/10.1056/NEJMe2408591>

## Notes from the Field

### Differences in Suicide Rates, by Race and Ethnicity and Age Group — United States, 2018–2023

Deborah M. Stone, ScD<sup>1</sup>; Alison L. Cammack, PhD<sup>1</sup>;  
Eric G. Carbone, PhD<sup>1</sup>

Suicide (death caused by injuring oneself with intent to die) is a serious U.S. public health problem (1) and ranks among the top eight leading causes of death among persons aged 10–64 years ([Facts About Suicide CDC](#)). From 2003 to 2023, age-adjusted suicide rates increased 31% (2), reaching 14.2 suicides per 100,000 population in 2018, the highest rate since 1941 (3). Suicide rates subsequently declined to 13.9 in 2019 and to 13.5 in 2020 but increased again in 2021 to 14.1 and remained essentially unchanged in 2022 (14.2) and 2023 (14.1) (2). This report updates a previous report that noted racial, ethnic, and age group differences in suicide rates during 2018–2021 (4) by extending the analytic period through 2023 and examines rate differences between 2021 and 2023.

### Investigation and Outcomes

#### Data Source and Analysis

Data from CDC's National Vital Statistics System multiple cause-of-death mortality files for 2018–2023 were analyzed (2). Age-adjusted suicide rates and 95% CIs were calculated by the [direct method](#) and using the 2000 U.S. standard population with [U.S. Census Bureau postcensal single-race estimates](#). Hispanic or Latino (Hispanic) ethnicity includes persons of any race, and all named racial groups were considered non-Hispanic. Persons with unknown ethnicity were excluded from race and ethnicity analyses, and, owing to small numbers, children aged <10 years were excluded from age-specific analyses; all suicide deaths were included in the total. Differences in suicide rates from 2018 to 2023 as well as from 2021 to 2023 were compared using z-tests when the number of suicide deaths was at least 100; p-values <0.05 were considered statistically significant. When the number of suicide deaths was less than 100, differences were considered significant if CIs based on a gamma distribution did not overlap. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.\*

\*45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

#### Summary

##### What is already known about this topic?

Suicide is among the top eight leading causes of death among persons aged 10–64 years; rates differed among demographic groups during 2018–2021.

##### What is added by this report?

During 2018–2023, U.S. suicide rates remained stable overall but differed among demographic groups. Rates increased among non-Hispanic Black or African American and Hispanic or Latino persons and decreased among non-Hispanic White persons and persons aged 10–24 years. Rates were highest among non-Hispanic American Indian or Alaska Native persons but declined between 2021 and 2023.

##### What are the implications for public health practice?

Implementation of evidence-based suicide prevention strategies in populations with high or increasing suicide rates could help save lives. CDC's Suicide Prevention Resource for Action provides a comprehensive approach to prevention, addressing the many factors associated with suicide.

#### Overall Age-Adjusted Suicide Rates, by Race and Ethnicity

In 2023, the overall U.S. age-adjusted suicide rate was 14.1 per 100,000. Rates were lowest among non-Hispanic Asian (Asian) persons (6.5) and highest among non-Hispanic American Indian or Alaska Native (AI/AN) (23.8), non-Hispanic White (White) (17.6), and non-Hispanic Native Hawaiian or Pacific Islander (NH/PI) persons (17.3) (Table) ([Supplementary Figure](#)). During 2018–2023, although overall U.S. age-adjusted suicide rates did not change, age-adjusted rates did change by race and ethnicity, increasing significantly among non-Hispanic Black or African American (Black) (25.2%) and Hispanic persons (10.0%) and declining significantly among White persons (3.1%). Rate differences among NH/PI persons were not significant because of small numbers. From 2021 to 2023, overall rates among AI/AN persons declined significantly (15.3%).

#### Suicide Rates, by Age Group

Between 2018 and 2023, overall U.S. suicide rates declined significantly among persons aged 10–24 (7.0%) and 45–64 years (6.7%) and increased among those aged 25–44 years (5.7%) (Table). Significant increases occurred among Black persons aged 10–24 (29.4%), 25–44 (29.2%), and 45–64 years (17.4%); Hispanic persons aged 25–44 years (25.2%); and White persons aged ≥65 years (3.6%). Rates

**TABLE. Suicide rates,\* rate changes, and annual number of suicide deaths, by race and ethnicity and age group — National Vital Statistics System, United States, 2018–2023**

Year, race and ethnicity <sup>†</sup>	Total no. of suicides	Age-adjusted rate <sup>§</sup>	Age group, yrs							
			10–24		25–44		45–64		≥65	
			No. of suicides	Rate	No. of suicides	Rate	No. of suicides	Rate	No. of suicides	Rate
<b>Total<sup>¶</sup></b>										
2018	48,344	14.2	6,807	10.7	15,541	17.9	16,885	20.1	9,102	17.4
2019	47,511	13.9	6,488	10.2	15,584	17.8	16,250	19.5	9,173	17.0
2020	45,979	13.5	6,643	10.5	15,768	17.9	14,409	17.4	9,137	16.4
2021	48,183	14.1	7,126	11.0	16,724	18.8	14,668	17.6	9,652	17.3
2022	49,476	14.2	6,533	10.0	16,848	18.9	15,645	19.0	10,438	18.1
2023	49,316	14.1	6,417	9.9	16,986	18.9	15,469	18.8	10,437	17.6
2023 vs. 2021 relative rate change, %**	NA	0.3	NA	−10.2 <sup>††</sup>	NA	0.4	NA	6.9 <sup>††</sup>	NA	1.9
2023 vs. 2018 relative rate change, %**	NA	−0.8	NA	−7.0 <sup>††</sup>	NA	5.7 <sup>††</sup>	NA	−6.7 <sup>††</sup>	NA	1.5
<b>Race and ethnicity</b>										
<b>American Indian or Alaska Native</b>										
2018	545	22.3	168	31.1	264	39.5	93	15.8	19	— <sup>§§</sup>
2019	546	22.5	160	29.9	266	39.3	96	16.4	24	8.0
2020	588	23.9	176	33.0	285	41.6	103	17.7	23	7.2
2021	692	28.1	196	36.3	365	52.8	96	16.4	35	10.7
2022	650	27.1	166	31.1	343	50.2	111	19.5	29	8.4
2023	577	23.8	133	25.3	312	45.1	105	18.5	27	7.4
2023 vs. 2021 relative rate change, %**	NA	−15.3 <sup>††</sup>	NA	−30.3 <sup>††</sup>	NA	−14.5 <sup>††</sup>	NA	12.4	NA	−30.5
2023 vs. 2018 relative rate change, %**	NA	6.9	NA	−18.6	NA	14.1	NA	16.8	NA	NA
<b>Asian</b>										
2018	1,315	6.7	292	8.5	451	7.2	383	8.2	189	8.0
2019	1,342	6.7	263	7.7	489	7.8	386	8.2	203	8.1
2020	1,302	6.4	253	7.4	466	7.4	365	7.6	218	8.3
2021	1,379	6.8	324	9.4	503	7.9	341	6.9	209	7.8
2022	1,459	6.9	286	8.0	543	8.3	400	7.9	230	8.1
2023	1,407	6.5	297	8.2	518	7.8	369	7.1	223	7.5
2023 vs. 2021 relative rate change, %**	NA	−3.9	NA	−12.4	NA	−1.4	NA	3.1	NA	−3.8
2023 vs. 2018 relative rate change, %**	NA	−3.0	NA	−3.0	NA	8.0	NA	−14.1 <sup>††</sup>	NA	−6.5
<b>Black or African American</b>										
2018	3,022	7.3	733	8.2	1,372	11.8	706	7.0	208	4.4
2019	3,115	7.5	749	8.5	1,428	12.1	717	7.1	217	4.4
2020	3,286	7.8	871	9.9	1,523	12.7	659	6.6	223	4.3
2021	3,692	8.7	1,001	11.2	1,758	14.5	693	6.8	234	4.4
2022	3,826	8.9	959	10.7	1,803	14.8	775	7.7	284	5.2
2023	3,911	9.1	945	10.7	1,873	15.2	827	8.2	264	4.7
2023 vs. 2021 relative rate change, %**	NA	4.1	NA	−5.1	NA	4.9	NA	20.3 <sup>††</sup>	NA	4.9
2023 vs. 2018 relative rate change, %**	NA	25.2 <sup>††</sup>	NA	29.4 <sup>††</sup>	NA	29.2 <sup>††</sup>	NA	17.4 <sup>††</sup>	NA	6.7
<b>Hispanic or Latino</b>										
2018	4,313	7.4	1,105	7.3	1,856	10.3	1,023	8.6	329	7.4
2019	4,331	7.3	1,146	7.5	1,864	10.3	1,042	8.5	274	5.9
2020	4,571	7.5	1,209	7.9	2,077	11.3	944	7.5	335	6.9
2021	4,907	7.9	1,250	7.9	2,291	12.3	1,015	7.8	350	6.9
2022	5,122	8.1	1,251	7.7	2,366	12.6	1,150	8.6	353	6.7
2023	5,281	8.2	1,258	7.7	2,477	12.9	1,150	8.3	394	7.1
2023 vs. 2021 relative rate change, %**	NA	3.4	NA	−2.4	NA	4.6	NA	7.1	NA	1.8
2023 vs. 2018 relative rate change, %**	NA	10.0 <sup>††</sup>	NA	5.0	NA	25.2 <sup>††</sup>	NA	−3.1	NA	−5.2

See table footnotes on the next page.

**TABLE. (Continued) Suicide rates,\* rate changes, and annual number of suicide deaths, by race and ethnicity and age group — National Vital Statistics System, United States, 2018–2023**

Year, race and ethnicity†	Total no. of suicides	Age-adjusted rate§	Age group, yrs							
			10–24		25–44		45–64		≥65	
			No. of suicides	Rate	No. of suicides	Rate	No. of suicides	Rate	No. of suicides	Rate
Native Hawaiian or Pacific Islander										
2018	73	11.9	19	—	41	21.7	11	—	<10	—
2019	90	14.4	21	16.6	50	25.9	16	—	<10	—
2020	79	12.5	24	18.9	37	18.9	17	—	<10	—
2021	82	12.6	21	16.2	45	22.7	14	—	<10	—
2022	95	14.3	28	21.1	51	25.6	12	—	<10	—
2023	116	17.3	25	18.6	63	31.2	24	16.2	<10	—
2023 vs. 2021 relative rate change, %**	NA	37.4	NA	14.9	NA	37.4	NA	NA	NA	NA
2023 vs. 2018 relative rate change, %**	NA	46.0	NA	NA	NA	43.8	NA	NA	NA	NA
White										
2018	38,415	18.1	4,305	12.9	11,315	23.3	14,489	26.1	8,302	20.7
2019	37,428	17.7	3,976	12.0	11,228	23.0	13,818	25.3	8,401	20.4
2020	35,442	16.9	3,912	12.0	11,076	22.7	12,161	22.6	8,289	19.7
2021	36,681	17.4	4,117	12.4	11,429	23.3	12,371	23.1	8,760	20.9
2022	37,481	17.6	3,647	11.0	11,383	23.3	12,975	24.8	9,473	21.9
2023	37,217	17.6	3,568	10.9	11,404	23.3	12,805	24.9	9,439	21.4
2023 vs. 2021 relative rate change, %**	NA	0.7	NA	−11.9††	NA	0.2	NA	7.7††	NA	2.7
2023 vs. 2018 relative rate change, %**	NA	−3.1††	NA	−14.8††	NA	0.1	NA	−4.6††	NA	3.6††
Multiracial										
2018	514	9.0	162	7.2	215	13.1	107	11.4	29	7.2
2019	527	8.8	166	7.2	231	13.5	110	11.6	20	4.7
2020	599	9.6	189	8.0	275	15.4	109	11.3	26	5.7
2021	631	9.7	203	8.2	294	15.8	99	10.0	35	7.4
2022	682	10.5	190	7.4	317	16.4	151	14.9	24	4.7
2023	628	9.2	183	7.0	284	14.1	123	12.0	37	6.9
2023 vs. 2021 relative rate change, %**	NA	−5.7	NA	−14.2	NA	−10.7	NA	19.9	NA	−6.7
2023 vs. 2018 relative rate change, %**	NA	2.3	NA	−2.8	NA	7.8	NA	4.8	NA	−4.1

**Abbreviation:** NA = not applicable.\* Suicide deaths per 100,000 population. Suicide deaths were identified using *International Classification of Diseases, Tenth Revision* underlying cause-of-death codes U03, X60–X84, and Y87.0.† Data for Hispanic or Latino (Hispanic) origin should be interpreted with caution; studies comparing Hispanic origin on death certificates and on U.S. Census Bureau surveys have shown inconsistent reporting on Hispanic ethnicity. Potential racial misclassification might lead to underestimates for certain categories, primarily American Indian, Alaska Native, Asian, and Pacific Islander decedents ([National Center for Health Statistics, Series 2, no 172 \(8/10/16\)](#)). Single-race estimates are presented and might not be comparable to earlier years produced by bridging multiple races to a single race choice. Hispanic ethnicity includes persons of any race. Racial groups exclude persons of Hispanic ethnicity. Persons with unknown ethnicity are excluded from race and ethnicity groups but are included in the overall total.§ Age-adjusted rates (number of suicide deaths per 100,000 population) were calculated using the direct method and the 2000 U.S. Census Bureau standard population. [Age adjustment - Health, United States](#)

¶ Includes decedents of unknown ethnicity and children aged &lt;10 years.

\*\* Relative rate change was calculated using the following equations: [(2023 rate – 2018 rate) / 2018 rate] x 100 and [(2023 rate – 2021 rate) / 2021 rate] x 100. Rates were rounded to four decimal places for all calculations and rounded to one decimal place in the table. Data were accessed on CDC WONDER on June 3, 2025.

†† Statistically significant at p&lt;0.05 for 2018–2023 and 2021–2023 rate difference based on z-test for at least 100 deaths. If either rate was based on less than 100 deaths, differences in rates were considered significant if CIs based on a gamma distribution did not overlap.

§§ Dashes indicate rates are considered unreliable or are suppressed when the rate is calculated with a numerator of &lt;20 or the data meet the criteria for confidentiality constraints (less than 10 deaths).

decreased significantly among Asian persons aged 45–64 years (14.1%) and among White persons aged 10–24 (14.8%) and 45–64 years (4.6%).

During 2021–2023, among persons aged 10–24 years, significant declines in rates occurred overall (10.2%) and among White (11.9%) and AI/AN (30.3%) persons. In addition, rates declined significantly among AI/AN persons aged

25–44 years (14.5%). Among persons aged 45–64 years, significant increases in suicide rates were observed overall (6.9%) and among Black (20.3%) and White persons (7.7%).

### Preliminary Conclusions and Actions

Although overall suicide rates remained stable during 2018–2023, rates and changes in rates over time differed by



race and ethnicity and age group. Rates increased overall among Black and Hispanic populations and declined overall among White persons and persons aged 10–24 years. Overall suicide rate increases among Black persons are particularly concerning as they continue rate increases described in the previous report (2018 to 2021) (4). Conversely, reductions in rates among persons aged 10–24 years are noteworthy given that a previous analysis identified a 62.0% rate increase in this age group during 2007–2021 ([NCHS Data Brief, Number 471, June 2023](#)). During 2021–2023, rates declined among AI/AN persons, overall, after previous increases (4); though rates still remain highest in this group.

There is no single cause of suicide. Rates and rate changes likely reflect the interaction of individual, relationship, community, and societal factors that affect groups differently (5). The National Strategy for Suicide Prevention (1) calls for a whole-of-society public health approach to prevention. [CDC's Comprehensive Suicide Prevention program](#) and its Suicide Prevention Resource for Action (5) support populations at increased risk for suicide and prioritize strategies with the best available evidence. Together, community-based approaches, such as strengthening economic supports and increasing connectedness, and health care–based strategies can save lives<sup>†</sup> (5).

<sup>†</sup> For persons in crisis, help is available through the U.S. Substance Abuse and Mental Health Services Administration's 988 Suicide & Crisis Lifeline (<https://www.988lifeline.org>) or by texting or calling 988.

Corresponding author: Deborah M. Stone, [za9@cdc.gov](mailto:za9@cdc.gov).

<sup>1</sup>Division of Injury Prevention, National Center for Injury Prevention and Control, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

## References

1. US Department of Health and Human Services. National strategy for suicide prevention. Washington, DC: US Department of Health and Human Services; April 2024. <https://www.hhs.gov/programs/prevention-and-wellness/mental-health-substance-use-disorder/national-strategy-suicide-prevention/index.html>
2. CDC. Suicide data and statistics. Atlanta, GA: US Department of Health and Human Services, CDC. Accessed Aug 21, 2025. <https://www.cdc.gov/suicide/facts/data.html>
3. Luo F, Florence CS, Quispe-Agnoli M, Ouyang L, Crosby AE. Impact of business cycles on US suicide rates, 1928–2007. *Am J Public Health* 2011;101:1139–46. PMID:21493938 <https://doi.org/10.2105/ajph.2010.300010>
4. Stone DM, Mack KA, Qualters J. Notes from the field: recent changes in suicide rates, by race and ethnicity and age group—United States, 2021. *MMWR Morb Mortal Wkly Rep* 2023;72:160–2. PMID:36757870 <https://doi.org/10.15585/mmwr.mm7206a4>
5. CDC. Suicide prevention resource for action: a compilation of the best available evidence. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. <https://www.cdc.gov/suicide/resources/prevention.html>

## Erratum

---

### Vol. 74, No. RR-1

In the report “Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025,” the following errors occurred:

On page 6, in the second column of Box 2, the third bullet should have read, “For persons with long-acting injectable PrEP ARV exposure during the past **6 months**, a diagnostic HIV nucleic acid test (NAT) is recommended at the initial medical evaluation, in addition to an Ag/Ab HIV test (NEW\*: good practice statement, indirect data; existing recommendation).”

On page 14, in the second column, the second bullet should have read, “For persons with long-acting injectable PrEP ARV exposure during the past **6 months**, a diagnostic HIV nucleic acid test (NAT) is recommended at the initial medical evaluation, in addition to an Ag/Ab HIV test (good practice statement, indirect data; existing recommendation).”

On page 15, the fourth sentence in the first paragraph should have read, “Certain experts would include an HIV NAT in nPEP baseline testing, especially if the person has recently taken oral ARVs or had a cabotegravir injection during the past **6 months**.”

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the U.S. Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR* at <https://www.cdc.gov/mmwr/index.html>.

Readers who have difficulty accessing this PDF file may access the HTML file at <https://www.cdc.gov/mmwr/index2025.html>. Address all inquiries about the *MMWR* Series to Editor-in-Chief, *MMWR* Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to [mmwrq@cdc.gov](mailto:mmwrq@cdc.gov).

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

*MMWR* and *Morbidity and Mortality Weekly Report* are service marks of the U.S. Department of Health and Human Services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 0149-2195 (Print)